| Literature DB >> 30347850 |
Enas Mohamed Eliaser1, Jun Hui Ho2, Najihah Mohd Hashim3,4, Yaya Rukayadi5, Gwendoline Cheng Lian Ee6, Ahmad Faizal Abdull Razis7,8,9.
Abstract
Natural products, either pure compounds or standardized plant extracts, have provided opportunities for the discovery of new drugs. Nowadays, most of the world's population still relies on traditional medicines for healthcare purposes. Plants, in particular, are always used as traditional medicine, as they contain a diverse number of phytochemicals that can be used for the treatment of diseases. The multicomponent feature in the plants is considered a positive phytotherapeutic hallmark. Hence, ethnopharmacognosy has been the focus for finding alternative treatments for diseases. Melicope lunu-ankenda, also known as Euodia lunu-ankenda, is widely distributed in tropical regions of Asia. Different parts of M. lunu-ankenda have been used for treatment of hypertension, menstrual disorder, diabetes, and fever, and as an emmenagogue and tonic. It has also been consumed as salad and as a condiment for food flavorings. The justification of use of M. lunu-ankenda in folk medicines is supported by its reported biological activities, including its cytotoxic, antibacterial, antioxidant, analgesic, antidiabetic, and anti-inflammatory activities. This review summarizes the phytochemical compounds isolated from various parts of M. lunu-ankenda, such as root and leaves, and also its biological activities, which could make the species a new therapeutic agent for some diseases, including diabetes, in the future.Entities:
Keywords: Melicope lunu-ankenda; Rutaceae; biological activities; ethnopharmacognosy; phytochemical
Mesh:
Substances:
Year: 2018 PMID: 30347850 PMCID: PMC6222432 DOI: 10.3390/molecules23102708
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Main morphological differences between genera Euodia, Tetradium, and Melicope. Adapted from Hartley [5].
| Genus | Main Morphological Difference |
|---|---|
|
|
Seeds dull and roughened, discharge when follicle dehisces Leaves trifoliolate or unifoliolate Inflorescences axillary |
|
|
Seeds shiny and smooth, remain attached in the dehisced fruit Leaves pinnately compound Inflorescences terminal or terminal and from the axils of the uppermost leaves pair |
|
|
Seeds shiny and smooth, remain attached in the dehisced fruit Leaves trifoliolate, unifoliolate or simple Inflorescences axillary, lateral or rarely terminal |
The taxonomy of M. lunu-ankenda [9].
| Taxonomic Rank | Taxon |
|---|---|
| Kingdom | Plantae |
| Phylum | Tracheophyta |
| Class | Magnoliopsida |
| Order | Sapindales |
| Family |
|
| Genus |
|
| Species |
The group, chemical structure, and biological activity of some phytochemical compounds in M. lunu-ankenda.
| Group | Compound | Chemical Structure | Biological Activity | Ref. |
|---|---|---|---|---|
| Alkaloids | 4-Methoxy-1-methyl-2(1H)-quinolinone |
| Not reported | [ |
| Isolycodolin |
| Antibacterial | [ | |
| 3-(3-Methyl-2-butenyl)-4-[(3-methyl-2-butenyl)oxy]-2(1H)-quinolinone |
| Antiviral | [ | |
| Buchapine |
| Antiviral | [ | |
| Dictamnine |
| Antifeedant | [ | |
| Evolitrine |
| Antifeedant and anti-inflammatory | [ | |
| Kokusaginine |
| Not reported | [ | |
| Melicarpinone |
| Antidiabetic and anti-inflammatory | [ | |
| Roxiamine A |
| Inactive | [ | |
| Roxiamine B |
| Inactive | [ | |
| Roxiamine C |
| Inactive | [ | |
| Skimmianine |
| Antidiabetic and anti-inflammatory | [ | |
| γ-fagarine |
| Not reported | [ | |
| Chromenes | Alloevodionol |
| Antibacterial | [ |
| Evodione |
| Analgesic, anti-inflammatory, and Antibacterial | [ | |
| Isoevodionol |
| Not reported | [ | |
| Leptonol |
| Antipyretic, antioxidant, analgesic, and anti-inflammatory | [ | |
| Melilunumane |
| Not reported | [ | |
| Coumarins | 6-Deoxyhaplopinol |
| Chemopreventive | [ |
| Marmesin |
| Antiproliferative and chemopreventive | [ | |
| Melilunumarin A |
| Chemopreventive | [ | |
| Melilunumarin B |
| Chemopreventive (Weak) | [ | |
| Scopoletin |
| Antidiabetic and antioxidant | [ | |
| Umbelliferone |
| Not reported | [ | |
| Bergapten |
| Not reported | [ | |
| Coumaric acids |
| Inactive | [ | |
| Flavonoids | Isorhamnetin |
| Antidiabetic and antioxidant | [ |
|
| Antidiabetic | [ | ||
| Terpenoids | (E)-β-ocimene |
| Antibacterial | [ |
| Lupeol |
| Not reported | [ |
Brief description of functions or mechanisms of extracts and compounds isolated from M. lunu-ankenda.
| Extract/Compound | Cancer Cell | Function/Mechanism | Ref. |
|---|---|---|---|
| 60% ethanolic extract | HepG2 |
Exhibit cytotoxicity without affecting normal cell line (3t3-L1) | [ |
| Melilunumarin A | Raji |
Inhibit the TPA-induced Epstein-Barr virus early antigen (EBV-EA) activation | [ |
| 6-deoxyhaplopinol | |||
| Marmesin | A549 |
Inhibit cell proliferation Inhibit the TPA-induced Epstein-Barr virus early antigen (EBV-EA) activation | |
| KB | |||
| HUVECs, A549 & H1299 |
Inhibit VEGF-A-stimulated endothelial cell proliferation Prevent VEGF-A-induced endothelial cell migration and invasion Exhibit anti-angiogenic activity Suppress the expression and secretion of VEGF | [ |
Figure 1The mechanisms of cytotoxic/chemopreventive activity exhibited by marmesin. TPA, 12-O-tetradecanoylphorbol-13-acetate; EBV-EA, Epstein-Barr virus early antigen; Cdk, cyclin-dependent kinase; pRb, retinoblastoma protein; E2F, transcription factor E2F; P, phosphate; MMP-2, matrix metalloproteinase-2; VEGF-A, vascular endothelial growth factor A; FAK, focal adhesion kinase; Src, proto-oncogene tyrosine-protein kinase; ERK, extracellular signal-regulated kinase; Akt, protein kinase B; p70S6K, ribosomal protein S6 kinase beta-1; MEK, mitogen-activated protein kinase kinase; VEGFR-2, vascular endothelial growth factor receptor-2; ILK, integrin-linked kinase; HER2/neu, human epidermal growth factor receptor 2.
Brief description of functions or mechanisms of compounds isolated from M. lunu-ankenda for antidiabetic activity. ARE: antioxidant response element; DPPH: 2,2-diphenyl-1-picrylhydrazyl; iNOS: inducible nitric oxide synthase; NO: nitric oxide; Nrf-2: nuclear factor erythroid 2-related factor 2; ROS: reactive oxygen species; STZ: streptozotocin; t-BHP, tert-butyl hydroperoxide; TBA: thiobarbituric acid.
| Compound | Function/Mechanism | Ref. |
|---|---|---|
| Ethanolic extract |
Inhibit α-glucosidase activity (key enzyme in carbohydrate hydrolysis) | [ |
|
Stimulate dose-dependent glucose uptake in both 3t3-L1 and HepG2 cells | [ | |
| Isorhamnetin |
Protect hepatocytes against oxidative stress by activating Nrf2-ARE pathway Block t-BHP induced ROS production and cell death Inhibit invasion and migration of gastric cancer cells Inhibit the expression of iNOS and the production of NO in LPS-activated macrophages | [ |
|
Reduce the levels of DPPH radical, serum glucose and glycosylated proteins | [ | |
|
Protect serum and tissue mitochondria from lipid peroxidation Reduce TBA-reactive substance levels | ||
|
Exhibit antioxidant activity in STZ-induced diabetic rats | ||
| Scopoletin |
Reduce the levels of blood glucose and lipid in STZ-induced diabetic rats Regenerate pancreatic-β cells slightly | [ |
|
Reduce hyperthyroid and hyperglycemic conditions without hepatotoxic effects Inhibit hepatic lipid peroxidation Increase the activities of superoxide dismutase, catalase and glutathione Decrease the levels of serum thyroid hormone and glucose Reduce the activity of hepatic glucose-6-phosphatase | [ | |
| Skimmianine |
Exhibit anti-inflammatory activity and in vitro antidiabetic effects | [ |
| Melicarpinone |
Exhibit anti-inflammatory activity and in vitro antidiabetic effects | |
| 3,5,4′-trihydroxy-8,3′-dimethoxy-7-(3-methylbut-2-enoxy) flavone (OPF) |
Induce insulin release by acting on pancreatic β-cells (cultured RIN 5F cells) to reduce blood glucose levels, serum biochemical parameters and diabetic complications in STZ-induced diabetic rats. | [ |
Figure 2The mechanisms of antidiabetic activity exhibited by isorhamnetin. TBA, thiobarbituric acid; LDH, lactate dehydrogenase; PARP, poly (ADP-ribose) polymerase; ROS, reactive oxygen species; t-BHP, tert-butyl hydroperoxide; PPARγ, peroxisome proliferator-activated receptor gamma; JNK, c-Jun N-terminal kinase; IκBα, nuclear factor of kappa light polypeptide gene enhance in B-cells inhibitor, alpha; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; iNOS, inducible nitric oxide synthase; NO, nitric oxide; DPPH, 1,1-Diphenyl-2-picrylhydrazyl; ERK1/2, extracellular signal-regulated kinase 1 or 2; PKC δ, protein kinase C delta; AMPK, 5′ adenosine monophosphate-activated protein kinase; Nrf2, nuclear factor erythroid 2-related factor 2; Keap1, Kelch-like ECH-associated protein 1; ARE, antioxidant response element; HO-1, hemeoxygenase 1; Sesn2, sestrin2; GCL, glutamate-cysteine ligase; GSH, glutathione. Adapted from Yang et al. [53].
Figure 3The mechanisms of antidiabetic activity exhibited by scopoletin. GSH, glutathione; CAT, catalase; SOD, superoxide dismutase.